What are the dosage adjustments of mobosetinib/mobosetinib?

The recommended initial dose of Mobocertinib is 160 mg once daily, on an empty stomach or with food. It is not recommended to break or chew the tablets. Dose adjustment is mainly based on the patient's tolerance to adverse drug reactions, the impact of combined medication on metabolic pathways, and pharmacokinetic changes in specific groups (such as those with abnormal liver and kidney function). Common situations that require dose adjustment include the occurrence of grade ≥ 2 gastrointestinal adverse reactions (such as severe diarrhea, nausea, vomiting), or the occurrence of adverse events such as cardiotoxicity, rash, and elevated liver enzymes. Specific actions include suspending the medication, restarting after reducing the dose, or discontinuing the medication completely.

After adverse reactions are controlled, moboxetinib can be resumed at a maintenance dose of 120 mg or 80 mg. In cases of severe toxicity or uncontrollable side effects, doctors usually recommend permanent discontinuation of the drug. In addition, if patients are combined with strong CYP3A4 inhibitors (such as ketoconazole), inducers (such as rifampicin) or P-gp inhibitors, the dosage or frequency of moboxetinib also needs to be adjusted to avoid abnormal increases or decreases in blood concentrations.

It is worth noting that during the initial use or dose adjustment period of mobosetinib, it is recommended to conduct weekly follow-up, including blood routine, liver and kidney function and electrocardiogram examinations, to ensure that the drug is well tolerated and to intervene promptly before toxicity increases. All dosage adjustments should be made by professional oncologists based on individual responses and medication guidelines. Patients must not reduce the dosage or take it intermittently on their own, so as not to affect the therapeutic effect or induce mutational resistance.

The dosage adjustment strategy of mobosetinib reflects the "individualized and targeted" medication trend in modern cancer treatment. It is also an important means to improve the therapeutic effect and reduce the risk of side effects. It must be strictly implemented in clinical application.

Reference materials:https://en.wikipedia.org/wiki/Mobocertinib